TREA

Wipe formulation

Follow

Information

  • Patent Grant
  • 6737068
  • Patent Number
    6,737,068
  • Date Filed
    Monday, October 1, 2001
    24 years ago
  • Date Issued
    Tuesday, May 18, 2004
    21 years ago
Information
Abstract
The present invention relates to a liquid formulation for a feminine wipe. The preferred formulation has an anti-irritant agent, a pH adjuster namely citric acid, and at least one preservative.
Description




BACKGROUND OF THE INVENTION




1. Field of the Invention




The present invention relates to a formulation for a wipe. More particularly, the present invention relates to a wipe or towelette formulation that has an anti-irritant agent. The wipe is particularly useful for feminine cleansing, and may alternatively be used for adult personal hygiene.




2. Description of the Prior Art




A towelette or wipe is generally an absorbent sheet that is treated or pre-moistened with a liquid formulation. The liquid used in pre-moistening the sheet is generally an aqueous solution. The solution may have a surface active detergent, a humectant and, in some instances, also a fragrance.




U.S. Pat. No. 5,804,203 to Hahn et al. is directed to a topical composition for reducing skin irritation in animals comprising an irritant ingredient and an anti-irritant amount of aqueous-soluble strontium cation.




U.S. Pat. No. 4,772,501 to Johnson et al. is directed to a wet wipe product having a fibrous wipe, a liquid preservative composition, and an enclosure for the fibrous wipe and the liquid preservative composition. The liquid preservative composition consists essentially of: (a) a mixture of citric acid and sorbic acid as the preservative component; (b) water; and (c) optional ingredients selected from the group consisting of skin moisturizers and fragrance compounds.




SUMMARY OF THE INVENTION




It is an object of the present invention to provide a mild formulation for use in a wipe.




It is another object of the present invention to provide a mild wipe formulation that has an anti-irritant agent.




It is a further object of the present invention to provide such a mild wipe formulation that prevents or minimizes skin irritation and itching especially feminine itching.




These and other objects and advantages of the present invention are achieved by a mild wipe formulation that comprises an anti-irritant agent, citric acid and at least one preservative. In one embodiment of the present invention, the wipe formulation comprises an anti-irritant agent, a pH adjuster, namely citric acid, at least one preservative, and one or more of the following: a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative that specifically prevents mold, and a fragrance.











DETAILED DESCRIPTION OF THE INVENTION




The present invention is a liquid wipe formulation. This formulation is used primarily in a feminine wipe. The wipe formulation has an anti-irritant agent, a pH adjuster, namely citric acid, and at least one preservative.




The anti-irritant agent used in the present wipe formulation has been effective to clean, refresh and prevent further feminine itching. The anti-irritant agent is preferably one or more of the following: local anesthetics, analgesics, anesthetics, antipruitics, astringents, hydrocortisone preparations, keratolytics or any combinations thereof. The local anesthetics that can be used in the present invention include benzocaine, benzyl alcohol, dibucaine, dibucaine HCl, Dyclonine HCl, Lidocaine, Pramoxine HCl, Tetracaine, Tetracaine HCl, or any combinations thereof. The anti-irritant agent is preferably present in an amount from about 0.1 wt % up to about 50 wt % of the total weight of the liquid, wipe formulation. More preferably, the anti-irritant agent is preferably present in an amount about 9 wt % of the total weight of the liquid, wipe formulation.




When the anti-irritant agent is an anesthetic, it is preferably a mixture of the following local anesthetics, and preferably in the approximate amount, set forth below.















Local Anesthetics in percentage






by wt (wt %) of the wipe






formulation


























Benzocaine




 5.0-20.0







Benzyl alcohol




1.0-4.0







Dibucaine




0.25-1.0 







Dibucaine HCl




0.25-1.0 







Dyclonine HCl




0.5-1.0







Lidocaine




2.0-5.0







Pramoxine HCl




1.0







Tetracaine




0.5-1.0







Tetracaine HCl




0.5-1.0















The analgesic, anesthetic or antipruitic anti-irritant agents that can be used in the present wipe formulation include camphor, juniper tar, menthol or combinations thereof. When the anti-irritant agent is an analgesic, an anesthetic or an antipruitic, it is preferably in the following mixture, and in an approximate range, set forth below.















Analgesic, anesthetic and






antipruitic in wt % of the wipe






formulation


























Camphor




0.1-3.0







Juniper tar




1.0-5.0







Menthol




0.1-1.0















The astringents that can be used in the present wipe formulation include calamine, zinc oxide or any combination thereof. When the anti-irritant agent is an astringent, it is preferably in the following mixture, and preferably in the approximate range, set forth below.















Astringents in wt % of the wipe






formulation


























Calamine




5.0-25.0







Zinc oxide




5.0-25.0







Witch hazel




1.0-50.0















The hydrocortisone preparations that can be used in the present wipe formulation include hydrocortisone, hydrocortisone acetate or any combination thereof. If the anti-irritant agent is a hydrocortisone preparation, it is preferably present in the following mixture, and preferably in the approximate range, set forth below.















Hydrocortisone preparations in






wt % of the wipe formulation


























Hydrocortisone




0.25-0.5







Hydrocortisone




0.25-0.5







acetate















The keratolytics that can be used in the present wipe formulation include alcloxa, resorcinol or any combination thereof. When the anti-irritant agent is a keratolytic, it is preferably present the following mixture, and preferably in the approximate range, set forth below.















Keratolytics in wt % of the wipe






formulation


























Alcloxa




0.2-2.0







Resorcinol




1.0-3.0















The second ingredient of the present wipe formulation is a pH adjuster. The preferred pH adjuster is citric acid. Preferably, citric acid is present in an amount from about 0.01 wt % to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, the citric acid is present in an amount from about 0.05 wt % to about 0.5 wt %, and most preferably about 0.1 wt %, of the total weight of the wipe formulation. With the above amounts of pH adjuster, the wipe formulation is in a pH range from about 4.0 to about 6.0, and preferably from about 4.5 to about 5.0.




The present wipe formulation has at least one preservative. That preservative is preferably one or more of the following: sodium hydroxymethylglycinate, polyaminopropyl biguanide, quaternary ammonium compound, EDTA salt, EDTA fatty acid conjugate, alkanol especially ethanol, isopropyl alcohol, benzyl alcohol, paraben, sorbate, urea derivative, and isothiazolinone, or any combination thereof. The preferred preservative is sodium hydroxymethylglycinate. The preservative is preferably present in an amount from about 0.2 wt % to about 2 wt %, and more preferably about 0.5 wt %, of the total weight of the wipe formulation.




In one embodiment of the present invention, the liquid wipe formulation has an anti-irritant agent, a pH adjuster, namely citric acid, and at least one preservative. In another embodiment of the present invention, the wipe formulation has the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, and one or more of the following ingredients: a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance. In yet another embodiment of the present invention, the liquid wipe formulation includes the anti-irritant, the pH adjuster, namely citric acid, the at least one preservative, a humectant, a surfactant, a skin conditioning agent, an emulsifying agent, a chelating agent, a second preservative which specifically prevents mold, and a fragrance.




The humectant used in a wipe of the present invention is preferably one or more of the following: glycerol, propylene glycol, sorbitol urea, amino acid, polyol and other compounds with hygroscopic properties, or any combination thereof. The preferred humectant is propylene glycol. The humectant is preferably present in an amount from about 0.1 wt % up to about 2 wt % of the total weight of the liquid, wipe formulation. More preferably, the humectant is present in an amount about 0.5 wt %.




The surfactant that can be used in a wipe formulation of the present invention is preferably one or more of the following: alkylamido alkylamine, quaternary ammonium compound, phosphorus derivative, amphoteric imidazoline derivative, fatty sulfosuccinate ester and amide, ethoxylated sorbitan ester, betaine, alkoxylated alcohol, alkyl ether sulfate, disodium cocoamphodiacetate, cocamidopropyl betaine, PEG-80 glyceryl cocoate/PEG-30 glyceryl cocoate, decyl polyglucose, or any combinations thereof. The preferred surfactant is disodium cocoamphodiacetate. The surfactant is preferably present in an amount greater than about 0 to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, the surfactant is present in an amount about 0.10 wt % of the total weight of the wipe formulation.




The skin conditioning agent used in an embodiment of the present wipe formulation is preferably one or more of the following: botanical extract including aloe vera gel, ester including tocopherol acetate (vitamin E acetate), quaternary ammonium compound, asymmetrical carbonate, N-substituted carboxamide, urea or phosphine oxide, organic salt, or any combination thereof. The skin conditioning agent is preferably present in an amount greater than about 0 wt % up to about 1.25 wt % of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.02 wt % of the wipe formulation. The preferred skin conditioning agents are aloe vera gel and tocopheryl acetate. When used, aloe vera gel is preferably present in an amount greater than about 0 to about 1 wt % of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt %. When used, tocopheryl acetate (vitamin E acetate) is preferably present in an amount greater than about 0 to about 1.0 wt % of the total weight of the liquid formulation. More preferably, it is present in an amount about 0.01 wt % of the wipe formulation.




The emulsifying agent used in a wipe formulation of the present invention is any one or more of the following: sorbitan, alkoxylated fatty alcohol, alkylpolyglycoside, soap, alkyl sulfate, monoalkyl and dialkyl phosphate, alkyl sulphonate, acyl isothionate, or any combinations thereof. The preferred emulsifying agent is polysorbate 20. The emulsifying agent is preferably present in an amount greater than about 0 wt % to about 1 wt % of the total weight of the liquid, wipe formulation. More preferably, it is present in an amount about 0.25 wt % of the wipe formulation.




The chelating agent that can be used in a present wipe formulation is preferably one or more of the following: disodium EDTA (ethylenediamine tetraacetate), ethylene-diamine-tetra-acetic acid, (ethylenedioxy)-diethylene-dinitrilo-tetra-acetic acid, salicylaldoxime, quinolinol, triethylenetetramine, or any combinations thereof. The preferred chelating agent is disodium EDTA. The chelating agent is preferably present in an amount greater than about 0 wt % up to about 0.2 wt % of the total weight of the liquid, wipe formulation. More preferably, the chelating agent is present in an amount about 0.1 wt % of the wipe formulation.




A wipe formulation of the present invention may include a second preservative that is specifically present to prevent mold. The preferred second preservative is potassium sorbate. The second preservative is preferably present in an amount from about 0.1 wt % to about 0.3 wt % of the total weight of the liquid, wipe formulation. More preferably, the second preservative is present in an amount about 0.14 wt % of the wipe formulation.




A wipe formulation of the present invention may include a fragrance. Any conventional fragrance that is mild and does not adversely affect sensitive areas for females, or other adults, may be used. Preferably, the fragrance is present in an amount greater than about 0 wt % up to about 0.5 wt %, and more preferably about 0.05 wt %, of the total weight of the liquid, wipe formulation.




The one example of the subject liquid wipe formulation is listed in Table 1 in weight percents, along with acceptable ranges.
















TABLE 1












Subject









Formulation




Ranges*







Ingredient




(wt %)




(wt %)













Water




QS




QS







Witch Hazel




9




 1-50







Propylene Glycol




0.5




0.1-2  







Disodium Cocoamphodiacetate




0.1




0-1







Tocopheryl Acetate (Vitamin E




0.01




0-1







Acetate)







Aloe Vera Gel




0.01




0-1







Fragrance




0.05




  0-0.5







Polysorbate 20




0.25




  0-0.5







Preservative




0.5




0.2-2  







Disodium EDTA




0.1




  0-0.2







Potassium Sorbate




0.14




0.1-0.3







Citric Acid




0.1




0.01-1  







TOTAL




100




100















The wipe formulations of the present invention have therapeutic benefits. In addition, they prevent or minimize skin irritation and itching. Moreover, each of the wipe formulations of the present invention is mild. The wipe formulations of the present invention may be used as a feminine wipe and, in particular, prevent or minimize feminine itching.




It should be understood that the foregoing description is only illustrative of the present invention. Various alternatives and modifications can be devised by those skilled in the art without departing from the invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications and variances that fall within the scope of the appended claims.



Claims
  • 1. A liquid wipe or towellete formulation comprising an anti-irritant agent selected from the group consisting of analgesic, antipruitic, astringent, hydrocortisone preparation, keratolytic, and any combinations thereof; citric acid; and at least one preservative, wherein said at least one preservative is sodium hydroxymethylglycinate, and wherein the formulation is in a pH range from about 4.0 to about 6.0.
  • 2. The formulation of claim 1, wherein said is at least one selected from the group consisting of witch hazel, calamine, zinc oxide, and any combinations thereof.
  • 3. The formulation of claim 1, wherein said astringent is witch hazel.
  • 4. The formulation of claim 1, further comprising a fragrance.
  • 5. The formulation of claim 1, further comprising a humectant selected from the group consisting of glycerol, propylene glycol, sorbitol urea, amino acid, polyol, and any combinations thereof.
  • 6. The formulation of claim 5, wherein said humectant is present in an amount from about 0.1 wt % to about 2 wt % of the total weight of the formulation.
  • 7. The formulation of claim 1, further comprising a surfactant selected from the group consisting of alkylamido alkylamine, quaternary ammonium compound, phosphorus derivative, amphoteric imidazoline derivative, fatty sulfosuccinate ester and amide, ethoxylated sorbitan ester, betaine, alkoxylated alcohol, alkyl ether sulfate, disodium cocoamphodiacetate, cocamidopropyl betaine, PEG-80 glyceryl cocoate/PEG-30 glyceryl cocoate, decyl polyglucose, and any combinations thereof.
  • 8. The formulation of claim 7, wherein said surfactant is present in an amount greater than about 0 wt % to about 1 wt % of the total weight of the formulation.
  • 9. The formulation of claim 1, further comprising a skin conditioning agent selected from the group consisting of botanical extract, ester, quaternary ammonium compound, asymmetrical carbonate, N-substituted carboxamide, urea, phosphine oxide, organic salt, and any combinations thereof.
  • 10. The formulation of claim 9, wherein the skin conditioning agent is in an amount greater than about 0 wt % up to about 1.25 wt % of the total weight of the formulation.
  • 11. The formulation of claim 1, further comprising an emulsifying agent selected from the group consisting of: sorbitan, alkoxylated fatty alcohol, alkylpolyglycoside, soap, alkyl sulfate, monoalkyl and dialkyl phosphate, alkyl sulphonate, acyl isothionate, and any combinations thereof.
  • 12. The formulation of claim 11, wherein the emulsifying agent is in an amount greater than about 0 wt % to about 1 wt % of the total weight of the formulation.
  • 13. The formulation of claim 1, further comprising a chelating agent selected from the group consisting of disodium EDTA, ethylene-diamine-tetra-acetic acid, (ethylenedioxy)-diethlyene-dinitrilo-tetra-acetic acid, salicylaldoxime, quinolinol, triethylenetetramine, and any combinations thereof.
  • 14. The formulation of claim 13, wherein said chelating agent is present in an amount greater than about 0 wt % up to about 0.2 wt % of the total weight of the formulation.
  • 15. The formulation of claim 1, further comprising a second preservative that combats mold.
  • 16. The formulation of claim 15, wherein said second preservative is in an amount from about 0.1 wt % to about 0.3 wt % of the total weight of the formulation.
  • 17. The formulation of claim 15, wherein said second preservative is potassium sorbate.
US Referenced Citations (60)
Number Name Date Kind
2565887 Salfisberg Aug 1951 A
3414927 Worcester Dec 1968 A
3786615 Bauer Jan 1974 A
4309469 Varona Jan 1982 A
4383986 Dubash et al. May 1983 A
4692374 Bouchette Sep 1987 A
4732797 Johnson et al. Mar 1988 A
4737405 Bouchette Apr 1988 A
4741944 Jackson et al. May 1988 A
4772501 Johnson et al. Sep 1988 A
4781974 Bouchette et al. Nov 1988 A
4817790 Porat et al. Apr 1989 A
4818594 Albien et al. Apr 1989 A
4865221 Jackson et al. Sep 1989 A
4904524 Yoh Feb 1990 A
4941995 Richards Jul 1990 A
5049440 Bornhoeft, III et al. Sep 1991 A
5141803 Pregozen Aug 1992 A
5152996 Corey et al. Oct 1992 A
5215759 Mausner Jun 1993 A
5219646 Gallagher et al. Jun 1993 A
5256417 Koltisko Oct 1993 A
5439682 Wivell et al. Aug 1995 A
5447930 Nayak Sep 1995 A
5507968 Palaikis Apr 1996 A
5512199 Khan et al. Apr 1996 A
5599549 Wivell et al. Feb 1997 A
5629081 Richards et al. May 1997 A
5635469 Fowler et al. Jun 1997 A
5648083 Blieszner et al. Jul 1997 A
5658577 Fowler et al. Aug 1997 A
5665364 McAtee et al. Sep 1997 A
5683971 Rose et al. Nov 1997 A
5686088 Mitra et al. Nov 1997 A
5686089 Mitra et al. Nov 1997 A
5699912 Ishikawa et al. Dec 1997 A
5702992 Martin et al. Dec 1997 A
5716625 Hahn et al. Feb 1998 A
5728690 Chen Mar 1998 A
5733572 Unger et al. Mar 1998 A
5736128 Chaudhuri et al. Apr 1998 A
5750484 Falbaum et al. May 1998 A
5753245 Fowler et al. May 1998 A
5753246 Peters May 1998 A
5804203 Hahn et al. Sep 1998 A
5897856 Trinh et al. Apr 1999 A
5908617 Moore et al. Jun 1999 A
5915394 Rickard Jun 1999 A
5939050 Iyer et al. Aug 1999 A
5942214 Lucas et al. Aug 1999 A
5962399 Wulff et al. Oct 1999 A
5968539 Beerse et al. Oct 1999 A
5993792 Rath et al. Nov 1999 A
6001344 Villa et al. Dec 1999 A
6007799 Lee et al. Dec 1999 A
6015547 Yam Jan 2000 A
6015816 Kostyniak et al. Jan 2000 A
6033679 Woo et al. Mar 2000 A
6042839 Lahanas et al. Mar 2000 A
6048836 Romano et al. Apr 2000 A
Non-Patent Literature Citations (2)
Entry
Textbook of Organic Medicinal and Pharmaceutical Chemistry, Second Edition,'Edited by Wilson et al., 1954, p. 281-282.*
Wenninger et al., International Cosmetic Ingredient Dictionary and Handbook, Seventh Edition, vol. 2, The Cosmetic, Toiletry, and Fragrance Association, pp. 1637.